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Phenotypic anchoringChronic administration of high doses of hexavalent chromium [Cr(VI)] as sodium dichromate dihydrate (SDD)
elicits alimentary cancers inmice. To further elucidate key events underlying tumor formation, a 90-day drinking
water studywas conducted in B6C3F1 mice. Differential gene expression was examined in duodenal and jejunal
epithelial samples following 7 or 90 days of exposure to 0, 0.3, 4, 14, 60, 170 or 520 mg/L SDD in drinking water.
Genome-wide microarray analyses identiﬁed 6562 duodenal and 4448 jejunal unique differentially expressed
genes at day 8, and 4630 and 4845 unique changes, respectively, in the duodenum and jejunum at day 91. Com-
parative analysis identiﬁed signiﬁcant overlap in duodenal and jejunal differential gene expression. Automated
dose–response modeling identiﬁed >80% of the differentially expressed genes exhibited sigmoidal dose–
response curves with EC50 values ranging from 10 to 100 mg/L SDD. Only 16 genes satisfying the dose-
dependent differential expression criteria had EC50 values b10 mg/L SDD, 3 of which were regulated by
Nrf2, suggesting oxidative stress in response to SDD at low concentrations. Analyses of differentially
expressed genes identiﬁed over-represented functions associated with oxidative stress, cell cycle, lipid me-
tabolism, and immune responses consistent with the reported effects on redox status and histopathology at
corresponding SDD drinkingwater concentrations. Collectively, these data are consistent with amode of ac-
tion involving oxidative stress and cytotoxicity as early key events. This suggests that the tumorigenic ef-
fects of chronic Cr(VI) oral exposure likely require chronic tissue damage and compensatory epithelial
cell proliferation.
© 2011 Elsevier Inc.Open access under CC BY-NC-ND license.Introduction
Chromium is a naturally occurring element found in a variety of envi-
ronmental media including soils, sediments, water, and air. In the envi-
ronment, chromium occurs in the trivalent or hexavalent state [Cr(III)
and Cr(VI)] (Proctor et al., 2002). Both valences of chromium are widely
utilized in commerce, including applications in metal plating, wood
treating, leather tanning, metallurgy and the manufacture of color pig-
ments, and refractorymaterials (IARC, 1990). It has long been recognized
that Cr(III) occurs naturally and ubiquitously in most environmental
media, while Cr(VI) has only recently been discovered to also occur nat-
urally in groundwater (Oze et al., 2007). Analyses of Cr(VI) in U.S. drink-
ing water supplies indicate that many sources in California contain 1 to
5 ppb (CDHS, 2009), and that the mean Cr(VI) concentration across the
contiguous U.S. is 4.9 ppb (0.005 mg/L) based on data from 1654 potableCinco Ranch Blvd., Suite G265,
. Thompson).
-NC-ND license.groundwater sites (AWWA, 2004). Cr(VI) is typically present in water
sources at much lower concentrations than Cr(III), and the current fed-
eral maximum contaminant level (MCL) for total chromium (i.e. both
valence states) is 0.1 mg/L. This MCL, as compared with typical U.S. en-
vironmental Cr(VI) levels, warrants examination for the risks of chronic
exposure to the Cr(VI) valence at concentrations as high as 0.1 mg/L.
Chromium toxicity is valence state-speciﬁcwith Cr(III) possessing low
toxicity, whereas Cr(VI) compounds are classiﬁed as human carcinogens
based onelevated respiratory cancer incidence associatedwith certain oc-
cupational exposures (IARC, 1990). The structural similarity of Cr(VI) to
phosphate and sulfate anions facilitates its rapid cellular absorption and
transport relative to Cr(III), which does not readily diffuse across mem-
branes (Katz and Salem, 1993; O'Brien et al., 2003; Yusof and Malek,
2009; Nemec et al., 2010). Inside the cell, Cr(VI) is reductively metabo-
lized through reactive intermediates such as Cr(V) andCr(IV) to kinetical-
ly stable Cr(III) with the potential generation of reactive oxygen and
carbon radical species that cause cellular damage, including in vitro geno-
toxicity and Cr-DNA adduct formation (Shi et al., 1999; O'Brien et al.,
2003; Arivarasu et al., 2008; De Flora et al., 2008; Zhitkovich, 2011). It is
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tion and stability through alteration of cellular GSH/GSSG ratios (Han
et al., 2006; Townsend, 2007). Moreover, Cr(VI) alters the thioredoxin
system, which may further perturb redox signaling (Myers et al., 2011).
Cr(III) is also biologically active andmay be necessary for proper carbohy-
drate and glucose metabolism (Vincent, 2004; Di Bona et al., 2011).
A recent 2-year cancer bioassay conducted by the National Toxi-
cology Program (NTP, 2008) reported that Cr(VI), administered as so-
dium dichromate dihydrate (SDD) in drinking water, caused a dose-
dependent increase in duodenal and jejunal neoplasms in mice at
concentrations ≥60 mg/L SDD (i.e. ≥ 21 mg/L Cr(VI) or 4200 times
greater than the mean 0.005 mg/L Cr(VI) concentration in the U.S.
water sources). The NTP study reported macroscopic and microscopic
neoplastic and non-neoplastic lesions in rodents following chronic
exposures and identiﬁed the small intestine as a target tissue. A com-
prehensive investigation has been conducted of biochemical and ge-
nomic responses in target tissues preceding tumor formation to
further elucidate a mode of action (MOA) (Thompson et al., 2011a).
In this current study, complementary genome-wide gene expression
in the mouse duodenum and jejunum is reported.
Cr(VI)-induced differential gene expression has been evaluated
in human cells and cell lines, rat lung, rainbow trout, and primitive
eukaryotes (Ye and Shi, 2001; D'Agostini et al., 2002; Izzotti et al.,
2002; Pritchard et al., 2005; Dos Santos Ferreira et al., 2007; Gavin
et al., 2007; Hook et al., 2008; Joseph et al., 2008). In addition, recent
studies have characterized gene expression and protein changes in
the nontumorigenic human lung epithelial cell line BEAS-2B trans-
formed by exposure to low (0.25–5 μM)1 concentrations of Cr(VI)
(Azad et al., 2010; Sun et al., 2011). However, genome-wide gene ex-
pression proﬁling in target tissues that develop tumors following
chronic oral exposure is lacking. Microarray analysis enables the si-
multaneous assessment of all gene expression changes in a cell or tis-
sue, which can be used to support the development of the MOA as a
function of dose and time. As part of our evaluation, dose-dependent
gene expression was evaluated in female B6C3F1 mice following 7
and 90 days of continuous exposure to SDD in drinking water at con-
centrations that are carcinogenic in rodents, and at lower concentra-
tions more relevant to human exposure. Intestinal differential gene
expression was analyzed for over-represented functions and pheno-
typically anchored to complementary histopathologic, biochemical,
and dosimetry data in the small intestine (Thompson et al., 2011b).Materials and methods
Animal husbandry and study design. Test substance, animal husbandry,
and study design have been previously described (Thompson et al.,
2011b). Brieﬂy, Southern Research Institute (Birmingham, AL) obtained
5–7 week old female B6C3F1 mice (16–24 g) from Charles Rivers Labo-
ratories International, Inc. Animals were acclimated for a minimum of
7 days and fed ad libitum with irradiated NTP-2000 wafers (Zeigler
Bros, Gardners, PA). Mice were provided ad libitum access to drinking
water containing SDD dissolved in tap water at 0, 0.3, 4, 14, 60, 170
and 520 mg/L. Animals were euthanized using CO2 after 7 and 90 days
of exposure (referred to as day 8 and day 91 throughout the text). At
the time of sacriﬁce, intestinal sections were collected and ﬂushed
with ice-cold phosphate buffered saline. The duodenal and jejunal sec-
tions were cut longitudinally, and the epitheliumwas scraped using dis-
posable sterile plastic spatulas (VWR International) into vials containing
~1 ml of TRIzol (Invitrogen, Carlsbad, CA) and snap-frozen in liquid ni-
trogen. The samples were stored at −80 °C and shipped overnight on
dry ice toMichiganState University for geneexpression analysis. All pro-
cedures were carried out with the approval of the Institutional Animal
Care and Use Committee at Southern Research Institute.1 2 μM≈0.1 mg/L Cr(VI), the current MCL.RNA isolation. Frozen intestinal epithelial samples were homoge-
nized using a Mixer Mill 300 tissue homogenizer (Retsch, Germany).
Total RNA was isolated according to the manufacturer's protocol
with an additional acid phenol:chloroform extraction. Isolated RNA
was resuspended in RNA storage solution (Ambion Inc., Austin,
TX), quantiﬁed (A260), and quality was assessed by evaluation of
the A260/A280 ratio and by visual inspection of 1 μg total RNA on a
denaturing gel.
Microarray analysis. Dose-dependent changes in gene expression were
examined usingmouse 4×44 K Agilent whole-genome oligonucleotide
microarrays (version 1, Agilent Technologies, Inc., Santa Clara, CA).
Treated samples were co-hybridized with vehicle controls to individual
arrays according to the manufacturer's protocol (Agilent Manual:
G4140-90050 v. 5.0.1). All hybridizations were performed with three
independent biological replicates for treated and control tissues (i.e.,
RNA samples were not pooled) and independent labeling of each sam-
ple (Cy3 and Cy5, including dye swap) for each treatment group at each
time point (8 and 91 days). Microarray slides were scanned at 532 nm
(Cy3) and 635 nm (Cy5) on a GenePix 4000B scanner (Molecular
Devices, Union City, CA). Images were analyzed for feature and back-
ground intensities using GenePix Pro 6.0 software (Molecular De-
vices). All data passed our laboratory quality assurance protocol
(Burgoon et al., 2005) andwere deposited in TIMS dbZach dataman-
agement system (Burgoon and Zacharewski, 2007). Microarray ex-
perimental design is shown in Supplementary Fig. S1.
Microarray data were normalized using a semi-parametric ap-
proach (Eckel et al., 2005). The posterior probabilities were calculated
using an empirical Bayes method based on a per gene and dose basis
using model-based t-values (Eckel et al., 2004). Unless stated other-
wise, gene expression data were ranked and prioritized using |fold
change|>1.5 and statistical P1(t) value >0.999 criteria to identify dif-
ferentially expressed genes. P1(t) values represent the posterior
probability of gene activity on a per gene and treatment dose basis
using the model-based t-value (Eckel et al., 2004).
Functional gene annotation and statistical analysis. Annotation and
functional categorization of differentially regulated genes was per-
formed using Database for Annotation, Visualization and Integrated
Discovery (DAVID) (Dennis et al., 2003) and Ingenuity Pathway
Analysis (IPA, Ingenuity Systems, Redwood City, CA). Heatmaps
and hierarchical clusters were generated using MultiExperiment
Viewer (MeV v. 4.6.0) using the TM4 microarray software suite
(Saeed et al., 2003). QRT-PCR statistical analyses were performed
with SAS 9.2 (SAS Institute, Cary, NC). Unless stated otherwise, all
data were analyzed by analysis of variance (ANOVA) followed by Dun-
nett's post hoc test. Differences between treatment groups were consid-
ered signiﬁcant when pb0.05.
Dose–response modeling. Gene expression dose–response changes
using 8 and 91 day data were examined using ToxResponse Model-
er (Burgoon and Zacharewski, 2008). ToxResponse Modeler iden-
tiﬁes the best ﬁt within ﬁve different mathematical models
(linear, exponential, Gaussian, sigmoidal, and quadratic). The algo-
rithm then identiﬁes the best-ﬁt from the ﬁve best in-class models
to calculate half maximal effective concentration (EC50) values. Mi-
croarray datasets were ﬁrst screened to identify genes differentially
expressed (±2-fold (P1(t)>0.999)) in the 520 mg/L SDD group.
Probes with a best ﬁt sigmoidal model were retained for EC50 calcu-
lations. EC50 values were not calculated for probes exhibiting other
dose–response proﬁles.
Benchmark dose (BMD) modeling was also performed using
BMDExpress v1.4 (Yang et al., 2007). In contrast to ToxResponse
Modeler, BMDExpress uses Hill, power, linear and polynomial
models to ﬁt differential gene expression responses, and determine
a benchmark response (see below). The microarray data were
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dure (Thomas et al., 2007). Raw signals from the microarray data
were extracted and data were normalized using a semi-parametric
approach (Eckel et al., 2005) and log2 transformed. Missing signal
values in the array data were imputed as follows. For each probe and
treatment group, an average of the signal data was computed if there
were at least three values. That average signal for the probe/dose com-
bination was imputed for all missing signals. Probes with a treatment
group with two or fewer signal values were not examined. Hill,
power, linear and 2° polynomial models were run assuming constant
variance and the benchmark response (BMR) factor was set to 1.349
(Yang et al., 2007). For analysis of the distributionof BMDvalues, probes
with poor model ﬁts (i.e. pb0.1) and/or BMD values outside the range
of exposure (0.3–520 mg/L SDD) were removed.
Quantitative real-time PCR (QRT-PCR). A select number of genes identi-
ﬁed as differentially expressed in the microarray analysis, were veriﬁed
by QRT-PCR. Total RNA (1 μg) was reverse transcribed by SuperScript II
(Invitrogen) using an anchored oligo-dT primer as described by the
manufacturer. The cDNA (1 μl) was used as a template in a 30 μl PCR re-
action containing 0.1 μM of forward and reverse gene-speciﬁc primers,
3 mMMgCl2, 1 mMdNTPs, 0.025 IUAmpliTaq Gold, and 1× SYBRGreen
PCR buffer (Applied Biosystems, Foster City, CA). Supplementary Table
S1 provides the names, gene symbols, accession numbers, forward
and reverse primer sequences, and amplicon sizes. PCR ampliﬁcation
was conducted on an Applied Biosystems PRISM 7500 Sequence Detec-
tion System. cDNAs were quantiﬁed using a standard curve approach
and the copy number of each sample was standardized to 3 housekeep-
ing genes (Actb, Gapdh, andHprt) to control for differences in RNA load-
ing, quality, and cDNA synthesis (Vandesompele et al., 2002). For
graphing purposes (GraphPad Prism 5.0), the relative expression levels
were scaled such that the expression level of the time-matched control
group was equal to one.
Duodenal area measurements. Unstained duodenal tissue sections
(see Thompson et al., 2011b) were used to measure crypt and villous
area. Parafﬁn-embedded transverse duodenal sections for control
and treated animals (0.3–520 mg/L SDD) at days 8 and 91 (n=5
per group, 3 sections per animal) were stained for DNA using
Feulgen's stain, covered with glass coverslips, and analyzed by Ex-
perimental Pathology Laboratories, Inc. (EPL®; Sterling, VA). Sys-
tems used to collect and tabulate the image analysis data included:
an Olympus® BX51 research microscope enhanced with a 3-axis
computer-controlled stepping motorized stage system, focus mea-
surement controller and Z axis limit switch, and a vibration isolation
platform (Olympus America, Inc., Melville, NY); a DVC 2000C-00-GE-
MGF color digital video camera (Digital Video Camera Company,
West Austin, TX); Stereo Investigator software for Design Based Ste-
reology, Image Analysis, and 2D Anatomical Mapping, v. 8.11 (MBF
Bioscience, Williston, VT); Image-Pro® Plus (IPP — version 7.0,
Media Cybernetics, Silver Spring, Maryland). Unless otherwise stat-
ed, image analysis procedures were performed according tomethods
described in the EPL standard operating procedures. Using IPP soft-
ware, the total mucosal and villous areas were outlined manually
and the internal borders of these areas were determined automati-
cally by the software's “Count/Size” color segmentation tool and
user-deﬁned colorimetric criteria. Acquisition of measurements
was facilitated by user-created IPP macro subroutines. The crypt
area was calculated by subtracting the villous area from the total mu-
cosal area: Total crypt area (μm2)=total mucosa area (μm2)− total
villous area (μm2). In addition, a villous to crypt ratio (total villous
area/total crypt area) was also calculated. Note, the transverse sec-
tions were taken at the approximate midpoint of the duodenum,
and the areameasurements for each animal were taken from 3 entire
tissue sections.Results
Intestinal gene expression — day 8
Mouse intestinal epithelial gene expressionwas evaluated using Agi-
lent whole-genome 4×44 K oligonucleotide microarrays containing
21,307 unique annotated genes. Statistical analysis (|fold change|>1.5,
P1(t)>0.999) identiﬁed 6562 unique differentially expressed genes at
one or more doses in the duodenum (Fig. 1A). Using the same ﬁltering
criteria, 4448 unique differentially expressed genes were identiﬁed in
jejunal samples collected from the same mice (Fig. 1A). Comparative
analysis identiﬁed 3785 differentially expressed genes in both intestinal
samples following SDD exposure (Fig. 1B). To minimize exclusion of
genes bordering these cut-offs, ﬁltering criteria were relaxed (from
|fold change|>1.5, P1(t)>0.999 to |fold change|>1.2, P1(t)>0.9
for the union of only those genes identiﬁed as differentially expressed
using the |fold change|>1.5, P1(t)>0.999 criteria), which nearly dou-
bled the number of overlapping genes (Fig. 1C). This suggests that the
genes differentially expressed in the jejunum are a subset of the duode-
nal gene expression changes.
In general, the gene expression proﬁles in both intestinal seg-
ments were comparable, although duodenal gene expression exhib-
ited greater fold changes (−67.6- to 52.8-fold) compared to the
jejunum (−29.6- to 11.9-fold). Hierarchical clustering of the 3785
overlapping differentially expressed genes at day 8 (Fig. 2A) revealed
that low (≤14 mg/L SDD) and high doses (≥ 60 mg/L SDD) clustered
separately and exhibited comparable expression proﬁles (the same
genes were either induced or repressed) between the two intestinal
sections, with greater efﬁcacy in the duodenum.
Intestinal gene expression — day 91
Using the sameﬁltering criteria as for day8 analyses (i.e. |fold change|
>1.5, P1(t)>0.999), 4630 unique differentially expressed genes were
identiﬁed in the duodenal epithelium at day 91 (Fig. 1D), representing
a ~30% reduction in the total number of differentially expressed genes
when compared to day 8. SDD also elicited the differential expression
of 4845 unique genes in the jejunal epithelium,which showed signiﬁcant
overlap with duodenal gene expression changes (Figs. 1E–F). Relative
fold inductionwas comparable in both tissues (up to 21-fold), but jejunal
epithelium showed greater suppression (−92.8-fold) relative to duode-
num (−39.0-fold). Hierarchical clustering of the 3324 overlapping genes
at 91 days also showed comparable low and high treatment group clus-
tering, with two thirds of the genes being down-regulated (Fig. 2B).
The overlapping genes exhibited more comparable levels of induction
and repression at ≥60 mg/L SDD, while low doses (≤14 mg/L SDD)
showed minimal differential expression. As observed at day 8, relaxing
the ﬁltering criteria increased the number of overlapping duodenal and
jejunal genes.
Not surprisingly, DAVID and IPA analyses revealed differences in func-
tional annotation for non-overlapping differentially expressed genes at
low (0.3–14 mg/L SDD) and high (60–520 mg/L) treatment groups (227
vs. 7536 unique genes, respectively, |fold change|>1.4, P1(t)>0.95).
The primary functions for differentially expressed genes at ≤14mg/L
SDD were associated with amino acid metabolism, small molecule bio-
chemistry, cell-to-cell signaling and interaction, and cell morphology,
while differential expression at ≥60 mg/L SDD was linked to cell
cycle/cell death, cellular growth and proliferation and protein synthesis
(data not shown). In general, these gene changes and dose ranges are
consistent with the onset of apical responses (Thompson et al.,
2011b). For example, signiﬁcant increases in overall differential gene
expression and cytoplasmic vacuolization were observed at ≥60 mg/L
SDD but not at lower concentrations.
Comparisons of differentially expressed genes at day 8 vs. 91
revealed signiﬁcant overlaps between duodenal and jejunal sam-
ples (Supplementary Fig. S2). Selected duodenal and jejunal gene
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Fig. 1. Comparison of the dose-dependent increase in differentially expressed genes in the duodenum and jejunum (A–C) at day 8 and (D–F) at day 91. (A, D) Number of differen-
tially expressed genes (|fold change|>1.5, P1(t)>0.999) in the duodenum and jejunum after 7 days and 90 days of continuous exposure to SDD. Differentially expressed duodenal
and jejunal genes were compared using (B, E) stringent (|fold change|>1.5, P1(t)>0.999) and (C, F) relaxed (|fold change|>1.2, P1(t)>0.9) ﬁltering criteria. Numbers in Venn
diagrams represent unique genes. Duo — duodenum, Jej — jejunum.
16 A.K. Kopec et al. / Toxicology and Applied Pharmacology 259 (2012) 13–26expression responses at days 8 and 91 were veriﬁed by QRT-PCR
(Fig. 3). Supplementary Table S2 lists the 10 most induced and re-
pressed duodenal genes at each dose at day 91.
Quantitative dose–response modeling
Dose–response modeling of differential gene expression provides
relative chemical potency data in various tissues at various time
points. In addition, modeling can identify genes, pathways and bio-
logical functions that are responsive or affected by treatment. Differ-
entially expressed probes in the duodenum and jejunum samples that
were altered at least ±2-fold in the 520 mg/L SDD group and met thestatistical cut-off of P1(t)>0.999 were selected for dose–response
analysis using ToxResponse modeler (Burgoon and Zacharewski,
2008). A total of 3360 probes representing 2559 unique genes were
modeled for day 8, with ~80% having EC50 values between 10 and
100 mg/L SDD (Supplementary Fig. S3A). A similar trend was ob-
served in the jejunum, although fewer genes were modeled (Supple-
mentary Fig. S3B).
At day 91, ToxResponse modeler identiﬁed 1381 duodenal probes
(1045 unique genes) and 1349 jejunal probes (1049 unique genes)
exhibiting a sigmoidal dose–response, of which ~90% had EC50 values
between 10 and 100 mg/L SDD (Figs. 4A–B). Only 21 duodenal probes
(16 annotated genes) had EC50 values between 0.3 and 10 mg/L SDD
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Fig. 2. Hierarchical clustering of the overlapping differentially expressed genes (A) at 8 days and (B) at 91 days. The signiﬁcantly expressed overlapping genes between the duo-
denum and jejunum at 8 days (3785 genes from Fig. 1B) and at 91 days (3324 genes from Fig. 1E) were used for hierarchical clustering (average linkage, Pearson correlation)
using MeV software (gene tree was cropped out for simplicity). Red and green represent induced and repressed genes, respectively. Duo — duodenum, Jej — jejunum.
17A.K. Kopec et al. / Toxicology and Applied Pharmacology 259 (2012) 13–26(Table 1). Three of these genes (Gclc, Gsto2, and Akr1b8) exhibited
sigmoidal dose-dependent expression and are regulated by Nrf2,2
suggestive of oxidative stress activation at low SDD concentrations.
Compared to duodenal median EC50 at day 8 (46.4 mg/L SDD), day
91 modeling results yielded a slightly lower overall EC50 value
(39.4 mg/L SDD) (Fig. 5). In contrast, the jejunal median EC50 was
slightly higher at day 91 (55.4 mg/L SDD) relative to jejunal model-
ing results at day 8 (43.3 mg/L SDD) (Fig. 5). The median BMD and
95% lower conﬁdence interval (BMDL) values for the day 91 duode-
nal probes were 88 and 56 mg/L SDD, and 72 and 49 mg/L SDD for
the day 91 jejunal probes (Supplementary Fig. S4).Functional analysis and phenotypic anchoring
DAVID and IPA analyses of day 8 duodenal differential expression
identiﬁed over-represented functions associated with oxidative stress,
xenobiotics/carbohydrate/lipid metabolism, protein synthesis, molecular
transport, cell signaling, antigen processing and presentation, cell cycle
and DNA replication, recombination, and repair (Table 2). Consistent2 Nrf2 (nuclear factor, erythroid derived 2, like 2) is also known as Nfe2l2.with the gene expression overlap in Fig. 1, similar pathways and func-
tions were enriched in the jejunum at day 8 (Supplementary Table S3).
At day 91, over-represented functions could not be identiﬁed due to
the limited number of differentially expressed genes at≤14 mg/L SDD.
At higher concentrations, functions associated with immune response,
lipid metabolism, small molecule biochemistry, metabolism and cell
death were similarly over-represented in duodenum (Table 3) and je-
junum (Supplementary Table S4).
Table 4 lists selected genes with respective fold inductions and cor-
responding EC50 values, grouped according to the most over-
represented functional categories presented in Tables 2 and3. For exam-
ple, genes associated with immune response (e.g., Anxa2, Blnk, Ccl24,
Il1rl1, Il33 and Clec7a) were differentially expressed at days 8 and 91.
Genes associated with expression at both time points preceded and co-
incided with minimal histiocytic inﬁltration after 90 days of SDD expo-
sure. Several antigen processing and presentation genes, including
Ciita, Tap2, B2m, and Cd74 were signiﬁcantly suppressed (−1.6- to
−7.9-fold) following Cr(VI) exposure. At day 91, Il1b was signiﬁcantly
decreased 1.5-fold at≥60 mg/L SDD, and Tnfwasmoderately repressed
(1.4-fold) at ≥60mg/L SDD. These ﬁndings are consistent with de-
creases in pro-inﬂammatory cytokines TNFα and IL-1β in the duode-
num at ≥60 mg/L SDD (Thompson et al., 2011b).
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Fig. 3. QRT-PCR veriﬁcation of Cyp1a1, Cyp2b10, Cyp3a11, andMyc expression in (A) duodenal and (B) jejunal epithelium at 8 days, and in (C) duodenal and (D) jejunal epithelium at 91 days. The same RNA used for Agilent microarrays was
examined by QRT-PCR. All fold changes were calculated relative to the time-matched vehicle controls. Bars (left y-axis) and lines (right y-axis) represent QRT-PCR and microarray data, respectively, with the x-axis representing the SDD
concentrations. The genes are displayed by their ofﬁcial gene symbols. The data are represented as mean±standard error (SE) of ﬁve independent replicates. Asterisks (*) indicate a signiﬁcant change (pb0.05) for QRT-PCR results.
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Fig. 4. Dose–response modeling of (A) duodenal and (B) jejunal datasets at day 91 categorized according to their EC50 value. ToxResponse modeler performed automated dose–
response modeling by identifying the best ﬁt model that is used to calculate EC50 values. A signiﬁcant number of differentially expressed genes exhibited a sigmoidal dose–response
proﬁle, of which ~90% had EC50 values between 10 and 100 mg/L SDD, even at greater range of absolute fold changes.
19A.K. Kopec et al. / Toxicology and Applied Pharmacology 259 (2012) 13–26SDD induced (~1.5- to 6.7-fold) several redox-sensitive Nrf2 tran-
scription factor targets, including Atf4, Gpx1, Gpx2, Gsr, Mt1, Prdx1, and
Stip1 (Table 4). These genes are involved in antioxidant, detoxiﬁcation,
and cytoprotective functions. Induction of genes associated with the
Nrf2 pathway (IPA canonical pathway is shown in Supplementary Fig.
S5) suggests activation of defensemechanisms in response to oxidative
stress, consistent with the reduced GSH/GSSG ratio and elevated pro-
tein carbonyls (oxidation) in duodenum (Thompson et al., 2011b). Car-
bonyl reductase (Cbr3), also regulated by Nrf2 (Ebert et al., 2010), was
elevated at the four lowest concentrations at day 91 (Supplementary
Table S2). Out of 57 unique mouse Nrf2 target genes (from IPA Nrf2-
mediated oxidative stress response canonical pathway), SDD elicited
the dose-dependent differential expression (induced and repressed)of 42–68% of all Nrf2 targets in the duodenum or jejunum at 8 and
91 days (|fold change| >1.5, P1(t)>0.999). When the ﬁltering criteria
were relaxed (|fold change| >1.2, P1(t)>0.90), the number of differen-
tially expressed Nrf2 pathway associated genes increased to 73–87%
(Supplementary Table S5). In addition to genes in the Nrf2 pathway,
SDD also induced (up to 6-fold)members of the glutathione transferase
and peroxidase families, including Gsto2, Gstt2, Gstm2, Gstm5, Gsta3,
Gsta4, Gstp1, and Gpx2 (Supplementary Table S5), further suggesting
an oxidative stress response.
Nrf2 activation can also be linked to increases in duodenal GSH
levels (Thompson et al., 2011b). Gene expression of glutamate–cyste-
ine ligase catalytic subunit (Gclc), the rate-limiting enzyme in
GSH synthesis (reviewed in Dickinson and Forman (2002)), was
Table 1
Functional annotation of genes with EC50 valuesb10 mg/L SDD in duodenum at day 91.
Gene
symbol
Gene name EC50* Direction Description
Gpr98 G protein-coupled receptor 98 4.2 ↓ GPCR expressed in central nervous system.
Gm9558 Predicted gene 9558 4.4 ↑ Metal ion binding.
Smpd2 Sphingomyelin
phosphodiesterase 2, neutral
4.8 ↓ Lysophospholipase
Ptprf Protein tyrosine phosphatase,
receptor type, F
5.3 ↓ This PTP was shown to function in the regulation of epithelial cell–cell contacts at adherents junctions, as well
as in the control of beta-catenin signaling.
Cyp4f18 Cytochrome P450, family 4,
subfamily f, polypeptide 18
5.9 ↓ The enzyme starts the process of inactivating and degrading leukotriene B4, a potent mediator of
inﬂammation.
Gbp6 Guanylate binding protein 6 6.3 ↓ Induced by interferon and hydrolyze GTP to both GDP and GMP.
Abca2 ATP-binding cassette, sub-family
A (ABC1), member 2
6.8 ↓ Highly expressed in brain tissue and may play a role in macrophage lipid metabolism and neural
development.
Insig2 Insulin induced gene 2 7.2 ↓ An endoplasmic reticulum protein that blocks the processing of sterol regulatory element binding proteins
(SREBPs) by binding to SREBP cleavage-activating protein (SCAP), and thus prevent SCAP from escorting
SREBPs to the Golgi.
Gsto2 Glutathione S-transferase omega
2
7.2 ↑ Involved in Nrf-2 mediated oxidative stress response, GSH metabolism, and xenobiotic metabolism.
Adap2 ArfGAP with dual PH domains 2 7.3 ↓ May be involved in metal ion binding.
Ciita Class II transactivator 8.3 ↓ Involved in transcription repression possibly involved in diseases of alimentary canal.
Cd244 CD244 natural killer cell receptor
2B4
8.6 ↓ Encodes a cell surface receptor expressed on natural killer (NK) cells (and some T cells) that mediate non-
major histocompatibility complex (MHC) restricted killing.
Akr1b8 Aldo-keto reductase family 1,
member B8
9.0 ↑ Involved in oxidation-reduction process; may have speciﬁcity for retinaldehyde.
Gclc Glutamate–cysteine ligase,
catalytic subunit
9.4 ↑ The ﬁrst and rate-limiting enzyme of glutathione synthesis.
Siae Sialic acid acetylesterase 9.6 ↓ This gene encodes an enzyme which removes 9-O-acetylation modiﬁcations from sialic acids. Mutations in
this gene are associated with susceptibility to autoimmune disease 6.
Hpgd Hydroxyprostaglandin
dehydrogenase 15 (NAD)
9.9 ↓ The encoded enzyme is responsible for the metabolism of prostaglandins, which function in a variety of
physiologic and cellular processes such as inﬂammation.
*EC50 values were calculated using ToxResponse Modeler (Burgoon and Zacharewski, 2008).
20 A.K. Kopec et al. / Toxicology and Applied Pharmacology 259 (2012) 13–26induced≥1.5-fold (P1(t)>0.99) in all treated groups relative to
untreated animals. As shown in Fig. 6, there were treatment-related in-
creases in Gclc mRNA and GSH at day 91, and induction of glutathione
peroxidase (Gpx1) at≥170 mg/L SDD. Together, these data suggest Nrf2
activation and redox related responses occur across several SDD concen-
trations after 7 and 90 days of exposure.
Genes associated with growth promotion, cell cycle and prolifera-
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Fig. 5. Box andwhiskers plot of EC50 value distributions for duodenum (Duo) and jejunum
(Jej) differential gene expression at days 8 and 91. The 75th,median, and the 25th percen-
tiles are depicted in the graph. ToxResponse Modeler (Burgoon and Zacharewski, 2008)
identiﬁed 2559 duodenal and 955 jejunal differentially expressed genes exhibiting sig-
moidal dose–response curves at day 8 with an overall median EC50 of 46 and 43 mg/L
SDD, respectively. At day 91, 1045 duodenal and 1049 jejunal differentially expressed
genes exhibited sigmoidal dose–response curves with an overall median EC50 of 39 and
55 mg/L SDD, respectively.at day 8. This included the induction (~1.6- to 52.7-fold) of trefoil fac-
tor 1 (Tff1), transcription factors like E2f2, Tfdp1, and Myc, as well as
several Myc target genes (e.g., Rcl1, Grpel1, Cdca7, Heatr1, Ttc27,
Nop56, and Mina) (Supplementary Fig. S6). These genes exhibit com-
parable dose-dependent induction with the highest efﬁcacy in the
duodenum at day 8 at ≥60 mg/L SDD. Induction of these genes pre-
ceded histological evidence of crypt hyperplasia at 520 mg/L SDD at
day 8, and at ≥170 mg/L SDD at day 91. Notably, Pcna was elevated
≥1.5-fold in the concentration preceding histological evidence of
crypt hyperplasia at day 91 (data not shown). In addition, several
Myc-regulated genes involved in DNA damage and repair were in-
duced 1.6- to 4.9-fold (predominantly at 170–520 mg/L SDD), and
therefore may be involved in cell proliferation as opposed to respond-
ing to DNA damage.Assessment of DNA repair genes and pathways
Induction of genes associated with oxidative stress suggests the
production of reactive oxygen species (ROS) that may lead to changes
in cell cycle and/or DNA damage. However, Cr(VI) exposure did not
increase 8-OHdG levels in the mouse duodenum in any treatment
group at day 91 (Thompson et al., 2011b). Several genes associated
with oxidative DNA damage and repair (Rusyn et al., 2004; Powell
et al., 2006), including Apex1, Brca1, Exo1, Xrcc6bp1, Ercc8, Rad51,
Msh2, and Rad54b, were induced (1.6- to 4.9-fold predominantly at
170–520 mg/L SDD) (Fig. 7, Table 4, Supplementary Table S6). Three
out of eight IPA canonical pathways related to DNA repair for the du-
odenum at 170 or 520 mg/L SDD at day 8 were enriched including nu-
cleotide excision repair (≥170 mg/L), mismatch repair in eukaryotes
(520 mg/L), and BRCA1 in DNA damage repair (520 mg/L). Notably
however, enrichment was not detected at day 91 (Supplementary
Table S7). No enrichment in the eight canonical DNA repair pathways
was detected in Cr(VI)-elicited jejunal differential gene expression at
day 8 or day 91 (Supplementary Table S8).
Table 2
Top 5 enriched canonical pathways and molecular and cellular functions — duodenum day 8.
Pathways Ratio* Molecular and cellular functions Genes
0.3 mg/L SDD
NRF2-mediated oxidative stress response 10/192 Carbohydrate metabolism 12
Xenobiotic metabolism signaling 11/299 Lipid metabolism 24
GSH metabolism 5/98 Molecular transport 26
Metabolism of xenobiotics by P450 6/213 Small molecule biochemistry 31
Circadian rhythm signalinga 3/35 Cell death 32
4 mg/L SDD
Xenobiotic metabolism signaling 12/299 Carbohydrate metabolism 13
Metabolism of xenobiotics by P450 6/213 Lipid metabolism 18
NRF2-mediated oxidative stress response 7/192 Molecular transport 20
GSH metabolism 4/98 Small molecule biochemistry 27
LPS/IL-1 mediated inhibition of RXR function 6/222 Drug metabolism 9
14 mg/L SDD
Caveolar-mediated endocytosis signaling 10/85 Cell death 80
Antigen presentation pathway 6/43 Antigen presentation 10
Autoimmune thyroid disease signaling 6/61 Cell signaling 4
Graft vs. host disease signaling 6/50 Nucleic acid metabolism 12
B cell development 5/37 Small molecule biochemistry 60
60 mg/L SDD
Cytotoxic T lymphocyte-mediated apoptosis 12/87 Protein synthesis 48
OX40 signaling pathway 12/96 Cellular assembly and organization 22
Allograft rejection signaling 10/97 Cell death 152
Autoimmune thyroid disease signaling 8/61 Cell morphologya 22
Graft vs. host disease signaling 8/50 Cellular developmenta 63
170 mg/L SDD
Fatty acid metabolism 39/196 Protein synthesis 132
Xenobiotic metabolism signaling 34/213 RNA post-transcriptional modiﬁcation 37
Arachidonic acid metabolism 39/225 Cell cycle 185
Linoleic acid metabolism 29/122 Cell death 350
Tryptophan metabolism 38/253 Lipid metabolism 129
520 mg/L SDD
Metabolism of xenobiotics by P450 49/213 Protein synthesis 179
Fatty acid metabolism 50/196 RNA post-transcriptional modiﬁcation 96
Tryptophan metabolism 49/253 Cell cycle 297
Pyrimidine metabolism 51/231 DNA replication, recombination, and repair 200
Arachidonic acid metabolism 46/225 Cellular assembly and organization 111
aDid not meet statistical signiﬁcance with Benjamini–Hochberg correction for multiple comparisons.
*Ratio is deﬁned as the number of differentially expressed genes (|fold change|>2.0, P1(t)>0.999) from the microarray dataset that maps to the pathway divided by the total
number of genes that map to the canonical pathway of interest.
21A.K. Kopec et al. / Toxicology and Applied Pharmacology 259 (2012) 13–26Duodenal area measurements
Although the gene expression changes noted herein are likely
the direct result of the test article (i.e. SDD), it is possible that mod-
est changes in the mucosal cell populations (i.e. proportions of
crypt and villous cells), with different inherent properties, may par-
tially contribute to the differential gene expression. As a proxy for
cell population, the areas of crypt and villous were measured at
each exposure concentration. At day 8, there were statistically sig-
niﬁcant decreases in the ratio of villous/crypt areas at 170 and
520 mg/L SDD (Fig. 8). At day 91, the villous/crypt ratio was signif-
icantly altered at 520 mg/L (Fig. 8). Functional analyses using
DAVID and IPA at day 8, revealed the enrichment of the samemolec-
ular and cellular functions between non-overlapping differentially
expressed genes at ≤60 mg/L and ≥170 mg/L SDD (1295 and
4176 unique genes, respectively, |fold change|>1.4, P1(t)>0.95).
Over-represented functions included RNA processing, cell cycle,
cell death, cell morphology, and cytoskeleton (data not shown). Similar
functional analysis at day 91 identiﬁed a total of 3954 genes at
≤170 mg/L and 1110 genes expressed only at 520 mg/L SDD (|fold
change|>1.4, P1(t)>0.95) with overlapping functions related to cell
cycle, cellular function and maintenance and post-translational modiﬁ-
cations (not shown).Discussion
This is the ﬁrst paper to report the genome-wide gene expression
effects of Cr(VI), in the form of SDD, on the mouse small intestine and
phenotypically associate differential gene expression to complemen-
tary histopathology, biochemical analyses, and tissue dosimetry.
SDD elicited dose-dependent differential gene expression in the duo-
denum and jejunum. Dose–response analysis indicates most changes
occur between 14 mg/L SDD (76 differentially expressed genes at
91 days) and 60 mg/L SDD (1857 differentially expressed genes at
91 days), with little differential expression below 4 mg/L SDD. Quan-
titative dose–response modeling of gene expression changes indicat-
ed that responses to SDD were similar in both intestinal segments at
both time points. The median EC50 values at day 8 and day 91 in the
duodenum and jejunum ranged from 39 to 55 mg/L SDD, whereas
the BMDL values at day 91 were 56 and 49 mg/L SDD in the duode-
num and jejunum, respectively. Dose-dependent gene expression
and associated functions are consistent with SDD concentrations
that elicited phenotypic effects (e.g. cytoplasmic vacuolization) de-
scribed in Thompson et al. (2011b). Taken together with no evidence
of focal proliferation or neoplastic lesions in two 90-day drinking
water studies (NTP, 2007; Thompson et al., 2011b) despite clear
signs of Cr(VI)-induced tissue injury (Fig. 8), it is highly plausible
Table 3
Top 5 enriched canonical pathways and molecular and cellular functions — duodenum day 91.
Pathways Ratio* Molecular and cellular functions Genes
0.3 mg/L SDD
Complement system 2/36 Cell death 3
Role of pattern recognition of bacteria and viruses 2/89 Carbohydrate metabolism 4
Type II diabetes mellitus signaling 2/163 Molecular transport 4
Insulin receptor signaling 2/141 Small molecule biochemistry 6
Acute phase response signaling 2/183 Lipid metabolism 4
4 mg/L SDD
Complement system 1/36 Lipid metabolism 1
Role of pattern recognition of bacteria and viruses 1/89 Small molecule biochemistry 2
Linoleic acid metabolism 1/122 Cell death 1
Metabolism of xenobiotics by P450 1/213 Cell-to-cell signaling and interaction 1
Fatty acid metabolism 1/196 Drug metabolism 1
14 mg/L SDD
Arachidonic acid metabolisma 2/225 Small molecule biochemistry 2
Xenobiotic metabolism signalinga 2/229 Carbohydrate metabolism 2
Granzyme A signalinga 1/20 Cell cycle 1
Maturity onset diabetes (MODY) signalinga 1/31 Cell morphology 2
G protein signaling mediated by Tubbya 1/141 Cell-to-cell signaling and interaction 2
60 mg/L SDD
Ca-induced T lymphocyte apoptosis 12/71 Cellular development 59
Cytotoxic T lymphocyte-mediated apoptosis 10/87 Cellular function and maintenance 42
Antigen presentation pathway 8/43 Cell-to-cell signaling and interaction 60
iCOS–iCOSL signaling in T helper cells 13/125 Antigen presentation 18
CTLA4 signaling in cytotoxic T lymphocytes 11/101 Cell death 79
170 mg/L SDD
Antigen presentation pathway 15/43 Lipid metabolism 123
Cytotoxic T lymphocyte-mediated apoptosis 19/87 Small molecule biochemistry 145
Allograft rejection signaling 16/97 Vitamin and mineral metabolism 46
OX40 signaling pathway 17/96 Cell death 241
Arachidonic acid metabolism 25/225 Protein synthesis 70
520 mg/L SDD
Cytotoxic L lymphocyte-mediated apoptosis 24/87 Cell death 247
Antigen presentation pathway 16/43 Lipid metabolism 138
Allograft rejection signaling 19/97 Small molecule biochemistry 210
OX40 signaling pathway 20/96 Vitamin and mineral metabolism 50
Autoimmune thyroid disease signaling 13/61 Cellular development 131
aDid not meet statistical signiﬁcance with Benjamini–Hochberg correction for multiple comparisons.
*Ratio is deﬁned as the number of differentially expressed genes (|fold change|>2.0, P1(t)>0.999) from the microarray dataset that maps to the pathway divided by the total
number of genes that map to the canonical pathway of interest.
22 A.K. Kopec et al. / Toxicology and Applied Pharmacology 259 (2012) 13–26that Cr(VI)-induced tumorigenicity is the result of constant tissue
damage and compensatory crypt epithelial cell proliferation. SDD-
elicited intestinal differential gene expression may also be partially
due to Cr(III) that is likely present at high concentrations following
the bolus reduction of Cr(VI) at the high SDD concentrations. Al-
though not as bioavailable due to passive uptake (Dayan and Paine,
2001), Cr(III) may alter carbohydrate/insulin signaling, and lipid me-
tabolism pathways (Vincent, 2004).
DAVID and IPA analyses of the differentially expressed genes identi-
ﬁed over-represented functions that could be phenotypically anchored
to several SDD-elicited biochemical and histological effects (Thompson
et al., 2011b). Enrichment analysis identiﬁed over-represented functions
related to cell development, maintenance, signaling, immune response
and cell death. Vacuolization was the most sensitive lesion observed in
themouse duodenum, beginning at 60 mg/L SDD andwas accompanied
by other lesions (e.g. villous atrophy and crypt hyperplasia) at 170 and
520 mg/L (Thompson et al., 2011b). There aremany causes of vacuoliza-
tion including altered lipidmetabolism, sequestration of absorbedmate-
rial, autophagy, endoplasmic reticulum (ER) stress and proteasome
dysfunction (Henics and Wheatley, 1999; Mimnaugh et al., 2006;
Franco and Cidlowski, 2009). Given that 60 mg/L SDD represents
Cr(VI) concentrations 4200 times higher than typical environmental
levels (see Introduction), the vacuoles could be due to sequestration of
chromium. Redox changes described throughout this paper couldindicate ER stress and accumulation of misfolded proteins. Altered ex-
pression levels of several proteosomal genes could indicate problems
with protein degradation and thus increased protein accumulation in
vacuoles. The over-representation of gene functions associated with
lipid metabolism, including the induction (~1.6–14.1-fold, data not
shown) of Scd2, Fasn, Acsl4, and Ldlr in the duodenum, is also consistent
with vacuolization. Further research is needed to understand vacuoliza-
tion in the intestinal mucosa in response to Cr(VI).
Interestingly, functional enrichment analysis indicated repression
of antigen presentation. Such an effect could result from toxicity to
the villous epithelium or the intestinal microbiota. In regard to the
former, it is well established that intestinal epithelial cells play a
role in regulating immune responses in the intestine, in part, through
processing and presentation of antigens to T-cells (Mayrhofer, 1995;
Yamada et al., 2009). The proteasome is required for both antigen
processing and presentation (Neurath et al., 1998; Elliott et al.,
2003; Reinstein, 2004), and thus repression of antigen presentation
and vacuolization (discussed above) might be interrelated. It is also
conceivable that suppression of antigen presentation is a result of
toxicity to the microbiota. Chowdhury et al. (2007) showed that the
intestinal transcript proﬁles are inﬂuenced by microbial colonization.
For example, B2m and Tap1 are elevated in normal piglet intestine rel-
ative to germ free piglet intestine (Chowdhury et al., 2007). B2m,
Tap1, and Tap2 were all decreased in the mouse small intestine in a
Table 4
Functional categorization and regulation of select intestinal genes identiﬁed as differentially expressed following exposure to 0.3–520 mg/L SDD.
Duodenum (day 8) Jejunum (day 8) Duodenum (day 91) Jejunum (day 91) 
Functional 
category
Gene 
ID
Gene name Gene 
symbol
Fold 
change*
EC50
b Fold 
change*
EC50
b Fold 
change*
EC50
b Fold 
change*
EC50
b
Im
m
un
e 
re
sp
on
se
12306 Annexin A2 Anxa2 −1.7 13.7 −1.6 6.0 1.6 62.0 1.3 NA
12330 Calnexin Canx 2.1 26.4 1.8 17.9 1.9 33.7 2.0 56.4 
17060 B-cell linker Blnk 1.9 53.8 1.7 17.8 1.6 86.6 1.6 68.0 
17082 Interleukin 1 receptor-like 1 Il1rl1 10.2 207.7 3.5 162.6 4.4 60.6 3.5 76.5 
77125 Interleukin 33 Il33 3.7 49.9 1.7 13.4 NC 12.3 1.6a 16.2 
56221 Chemokine (C-C motif) ligand 24 Ccl24 8.0 25.4 −5.1 NA 4.6 22.5 −3.6 NA
56644 C-type lectin domain family 7, member a Clec7a 3.5 44.5  2.6 194.4 3.3 52.8 3.3 17.5 
12265 Class II transactivator Ciita −1.6 NA NC 3.9 −5.7 8.3 −3.8 12.0 
21354 Transporter 1, ATP-binding cassette, 
sub-family B (MDR/TAP)
Tap1 −2.1 240.1 NC NA −3.8 35.1 −3.0 63.5
21355 Transporter 2, ATP-binding cassette, 
sub-family B (MDR/TAP)
Tap2 −3.9 152.1  −1.9 NA −5.0 47.9 −4.0 60.1 
21926 Tumor necrosis factor Tnf NC NA NC NA −1.4 NA NC NA
12010 Beta-2 microglobulin B2m −3.8 18.5  −2.5 NA −3.9 62.7 −4.0 58.7 
16149 CD74 antigen (invariant polypeptide of 
major histocompatibility complex, class 
II antigen-associated)
Cd74 −3.6 5.1  −2.0 7.2 −7.9 21.2 −3.8 14.0 
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11911 Activating transcription factor 4 Atf4 2.1 17.3  1.5 21.6 1.6 61.0 1.4 NA
14775 Glutathione peroxidase 1 Gpx1 2.6 24.4  2.4 16.2 1.5 17.7 1.7 50.8 
14776 Glutathione peroxidase 2 Gpx2 6.7 74.2  4.7 87.2 3.0 46.9 4.3 17.7 
14782 Glutathione reductase Gsr 3.2 16.5  2.3 25.9 2.2 70.1 2.8 32.0 
17748 Metallothionein 1 Mt1 3.1 4.6  3.2 7.0 3.9 54.4 5.0 39.3 
18024 Nuclear factor, erythroid derived 2, like 2 Nrf2(Nfe2l2) 1.6 28.8  1.6 NA 1.3 NA NC NA
18477 Peroxiredoxin 1 Prdx1 1.7 10.6  1.4a NA 1.9 17.9 1.7 19.1 
20867 Stress-induced phosphoprotein 1 Stip1 2.4 114.9  1.6 66.3 1.8 108.1 2.1 20.9 
20135 Ribonucleotide reductase M2 Rrm2 3.4 84.3  2.1 36.1 1.7 20.2 2.2 58.5 
18538 Proliferating cell nuclear antigen Pcna 2.2 58.4  1.6 17.5 1.7 15.3 1.7 49.1 
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12534 Cyclin-dependent kinase 1 Cdk1 3.2 30.2  2.5 81.3 2.0 162.4 2.5 19.7 
13197 Growth arrest and DNA-damage-
inducible 45 alpha
Gadd45a −2.4 64.3  −1.6 NA −1.7 NA −1.8 NA
21781 Transcription factor Dp 1 Tfdp1 2.4 15.3  1.3a NA 1.3 NA 1.5 18.9 
17713 GrpE-like 1, mitochondrial Grpel1 2.5 141.3  1.9 31.6 1.8 NA 1.9 17.4 
17869 Myelocytomatosis oncogene Myc 4.1 62.0  1.9 207.7 1.2a NA 1.3 NA
59028 RNA terminal phosphate cyclase-like 1 Rcl1 2.7 23.5  1.6 51.9 1.8 NA 2.2 34.6 
66953 Cell division cycle associated 7 Cdca7 2.2 51.1  NC NA NC NA 1.4a NA
67014 Myc induced nuclear antigen Mina 2.7 32.0  1.6 26.6 1.5 NA 1.4 NA
67134 NOP56 ribonucleoprotein homolog (yeast) Nop56 6.0 NA 2.9 67.1 2.0 32.2 2.2 60.3 
74196 Tetratricopeptide repeat domain 27 Ttc27 3.8 61.6  1.9 65.5 2.0 101.8 2.3 53.2 
217995 HEAT repeat containing 1 Heatr1 4.3 173.5  2.3 85.8 1.8 80.8 2.0 37.1 
21784 Trefoil factor 1 Tff1 52.7 113.8  3.8 NA NC NA 1.8 64.8 
242705 E2F transcription factor 2 E2f2 6.0 21.2  2.4 59.0 2.2 166.6 2.3 24.9 
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11792 Apurinic/apyrimidinic endonuclease 1 Apex1 4.9 37.9  2.3 17.5 1.9 62.3 2.7 108.8 
12189 Breast cancer 1 Brca1 2.5 18.4  1.5 53.2 1.6 55.4 1.7 51.5 
17350 MutL homolog 1 (E. coli) Mlh1 1.6 31.8  1.3a NA 1.3a NA 1.4 NA
17685 MutS homolog 2 (E. coli) Msh2 2.0 35.1  1.5 58.0 1.4a NA 1.5 12.4 
17688 MutS homolog 6 (E. coli) Msh6 1.8 143.9  1.3a NA NC NA 1.2 NA
19361 RAD51 homolog (S. cerevisiae) Rad51 4.2 56.8  2.4 73.2 2.1 NA 2.2 26.4 
26909 Exonuclease 1 Exo1 3.8 NA 1.8 NA 1.4a NA 1.8 107.9 
68876 XRCC6 binding protein 1 Xrcc6bp1 2.8 155.7  1.7 61.0 1.5 63.8 1.5 21.0 
71991 Excision repair cross-complementing 
rodent repair deficiency, 
complementation group 8
Ercc8 2.8 46.0  1.8 55.3 1.4 NA 1.6 8.9 
210766 BRCA1/BRCA2-containing complex, subunit 3 Brcc3 1.7 26.0  1.4 NA 1.6 NA 1.3 NA
623474 RAD54 homolog B (S. cerevisiae) Rad54b 2.1 67.7  1.5 NA NC NA 1.4a NA
*Maximum absolute fold change, P1(t)>0.999.
aMaximum absolute fold change, P1(t)>0.90.
bEC50 values were calculated using ToxResponse Modeler (Burgoon and Zacharewski, 2008).
NC — no change; genes did not meet an absolute fold change of at least 1.2 and P1(t)>0.90.
NA — not available, EC
50
values were not available for genes that did not meet the |fold change|>1.5 and P1(t)>0.999 cut-off in the 520 mg/L SDD group, or if the modeling
returned a Gaussian best ﬁt model.
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genes could relate to antimicrobial properties of Cr(VI). For example,
rats exposed to 10 mg/L Cr(VI) in drinking for 10 weeks exhibit al-
tered enzyme function in both intestinal epithelia and intestinal bac-
teria (Upreti et al., 2005). The 60–520 mg/L SDD concentrations in thecurrent study are even higher (~20–180 mg/L Cr(VI)), and 100 mg/L
Cr(VI) has been shown to be overtly toxic to intestinal bacteria in
vitro (Upreti et al., 2005). Interestingly, intestinal bacteria isolated
from rats exposed to 10 mg/L Cr(VI) for 10 weeks are more resistant
to Cr(VI) than bacteria from naïve rats (Shrivastava et al., 2005).
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Fig. 6. Duodenal measurements of GSH (left axis) and Gclc and Gpx1mRNA (right axis)
at day 91. Note that the mRNA levels of Gclc were increased≥1.5 fold in all treated
groups relative to untreated animals, while Gpx1 was signiﬁcantly (~2 fold) induced
at≥170 mg/L SDD. *pb0.05 for treated vs. control animals. Data for GSH were reported
in Thompson et al. (2011b).
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Fig. 8. Villous/crypt area ratios in the duodenum at days 8 and 91. The data are repre-
sented as mean±SE of ﬁve independent replicates (mice). Asterisks (*) indicate a sig-
niﬁcant (pb0.01) change relative to vehicle. Data were analyzed by ANOVA followed
by Dunnett's post hoc test.
24 A.K. Kopec et al. / Toxicology and Applied Pharmacology 259 (2012) 13–26Taken together, these ﬁndings suggest that chronic exposure to high
concentrations of Cr(VI) can alter the normal relationship between
intestinal microbiota and intestinal mucosae.
The concentrations at which most of the transcriptome changes
were observed are generally consistent with duodenal chromium
levels previously reported at day 91 (Thompson et al., 2011b). Fig. 9
shows a progression of increased tissue chromium concentration, de-
creased GSH/GSSG ratio, followed by differential gene expression
with over-represented functions consistent with SDD concentrations
that elicit histological changes. Although there is little differential
gene expression at ≤14 mg/L SDD at day 91, a few genes exhibit
dose-dependent differential expression at low concentrations. Inter-
estingly, several of these genes (Gclc, Gsto2, Cbr3, and Akr1b8) are
Nrf2 targets (Table 1, Supplementary Table S2). Chromate-mediated
activation of oxidative stress response genes (e.g. Mt2, Mtf1, Gpx,0.
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Fig. 7. Heatmap of select genes involved in oxidative DNA damage was created using MeV so
L SDD) in (A) duodenum and (B) jejunum at days 8 and 91.Sod) has also been reported in human lung type II epithelial cells
(A549) (Ye and Shi, 2001). Although tissue levels (Fig. 9) indicate
chromium was not greatly elevated at lower SDD concentrations,
studies suggest that intestinal cells regulate the extracellular (i.e. lu-
minal) redox environment, in part, through cysteine export (Dahm
and Jones, 2000; Moriarty-Craige and Jones, 2004; Go et al., 2009;
Mannery et al., 2010). Extracellular changes in the cysteine/cystine
(Cys/CySS) redox couple can result in gene expression changes relat-
ed to Nrf2 signaling and GSHmetabolism (Go et al., 2009). Thus, some
of the gene changes at ≤14 mg/L SDD may be responses to the extra-
cellular (i.e. luminal) environment as opposed to intracellular
environment.
Given the evidence of oxidative stress and the hypothesis that in-
testinal tumors may arise through a mutagenic MOA (McCarroll et al.,
2010; U.S. EPA, 2010), DNA damage and repair gene expression re-
sponses were investigated. SDD induced Apex1 nuclease which3
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Fig. 9. Comparison of total chromium tissue levels (in μg Cr per g of tissue) and duode-
nal gene expression changes (|fold change|>1.5, P1(t)>0.999) as a function of SDD
concentration in drinking water at day 91. Arrows indicate lowest tissue concentra-
tions associated with biochemical and histopathological effects as reported in Thompson
et al. (2011b).
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repair pathways (Gelin et al., 2010). Apex1 is directly regulated by
Myc (Watson et al., 2002), which was also induced by SDD. Concen-
trations of SDD of ≥60 mg/L also induced genes involved in double-
strand break repair via homologous recombination, including Brca1,
frequently dysregulated in breast and ovarian cancers, Exo1, and
Rad51 (Boulton, 2006; Kass and Jasin, 2010). Moreover, DNA mis-
match repair (MMR) genes (Mlh1, Msh2 and Msh6) were induced at
carcinogenic doses (≥170 mg/L SDD). As shown in Fig. 7 and Supple-
mentary Tables S6–S8, most of the signiﬁcant changes in DNA dam-
age and repair gene expression occurred at day 8 (primarily in the
duodenum), and were attenuated by day 91. Overall, these gene ex-
pression changes reﬂect responses to cellular oxidative stress, cell
death, proliferation, and/or DNA damage. Reports of no change in du-
odenal 8-oxoguanine levels (De Flora et al., 2008; Thompson et al.,
2011b) may reﬂect a lack of assay sensitivity or effective repair of ox-
idative DNA damage. A previous study with peroxisome proliferators
has reported no changes in 8-oxoguanine levels (measured by chro-
matographic methods), yet induction of DNA repair genes (Rusyn
et al., 2004). These ﬁndings suggest that gene expression is a more
sensitive biomarker for oxidative stress than other commonly used
endpoints (8-oxoguanine, abasic sites or single strand breaks).
In the NTP (2008) 2-year bioassay, 57 mg/L SDD resulted in in-
creased intestinal tumors (relative to historical but not concurrent
controls), whereas 14 mg/L was not associated with intestinal tu-
mors. The studies herein indicate most differential gene expression
occurred in the mouse small intestine at ≥60 mg/L SDD, which coin-
cided with the accumulation of intestinal chromium levels and the
occurrence of biochemical changes and apical histopathological le-
sions. The data provide compelling evidence that SDD elicited gene
expression changes associated with oxidative stress, cytotoxicity,
and regenerative cell proliferation, and that these are likely key
events in the MOA of Cr(VI) intestinal carcinogenesis. Comparable
ongoing studies in rats will further elucidate the species-speciﬁc
pharmacokinetic and pharmacodynamic differences that will inform
the MOA for intestinal tumors in mice, as well as the risk of Cr(VI) in-
gestion for humans.
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This work was funded by The Hexavalent Chromium Panel of the
American Chemistry Council.Conﬂict of interest
The authors declare that there are no conﬂicts of interest.
Acknowledgments
The authors would like to thank Drs. Michael Dourson, David Gaylor,
LucyAnderson, Rebecca Fry and Travis J. O'Brien for a critical reviewof an
earlier version of the manuscript. In addition, the authors also thank
Buddy Burkhalter for assistance with data handling, as well as Michelle
Angrish, Courtney Goslowsky, Michelle Thomas, Marsha Grimes,
Veronica Reardon, Lawanda Moon, and Sharell Lewis for their as-
sistance with tissue collections.
References
Arivarasu, N.A., Fatima, S., Mahmood, R., 2008. Oral administration of potassium di-
chromate inhibits brush border membrane enzymes and alters anti-oxidant status
of rat intestine. Arch. Toxicol. 82, 951–958.
AWWA, 2004. Low-level hexavalent chromium treatment options: bench-scale evalu-
ation. In: Brandhuber, P., Frey, M., McGuire, M., Chao, J.P., Seidel, C., Amy, G., Yoon,
J., McNeill, L., Banerjee, K. (Eds.), AWWA Research Foundation, Denver, CO.
Azad, N., Iyer, A.K., Wang, L., Lu, Y., Medan, D., Castranova, V., Rojanasakul, Y., 2010.
Nitric oxide-mediated bcl-2 stabilization potentiates malignant transformation of
human lung epithelial cells. Am. J. Respir. Cell. Mol. Biol. 42, 578–585.
Boulton, S.J., 2006. Cellular functions of the BRCA tumour-suppressor proteins. Bio-
chem. Soc. Trans. 34, 633–645.
Burgoon, L.D., Eckel-Passow, J.E., Gennings, C., Boverhof, D.R., Burt, J.W., Fong, C.J.,
Zacharewski, T.R., 2005. Protocols for the assurance of microarray data quality
and process control. Nucleic Acids Res. 33, e172.
Burgoon, L.D., Zacharewski, T.R., 2007. dbZach toxicogenomic information manage-
ment system. Pharmacogenomics 8, 287–291.
Burgoon, L.D., Zacharewski, T.R., 2008. Automated quantitative dose–response model-
ing and point of departure determination for large toxicogenomic and high-
throughput screening data sets. Toxicol. Sci. 104, 412–418.
CDHS, 2009. Chromium-6 in drinking water: an overview of sampling results.
Chowdhury, S.R., King, D.E., Willing, B.P., Band, M.R., Beever, J.E., Lane, A.B., Loor, J.J.,
Marini, J.C., Rund, L.A., Schook, L.B., Van Kessel, A.G., Gaskins, H.R., 2007. Transcrip-
tome proﬁling of the small intestinal epithelium in germfree versus conventional
piglets. BMC Genomics 8, 215.
D'Agostini, F., Izzotti, A., Bennicelli, C., Camoirano, A., Tampa, E., De Flora, S., 2002. In-
duction of apoptosis in the lung but not in the liver of rats receiving intra-
tracheal instillations of chromium(VI). Carcinogenesis 23, 587–593.
Dahm, L.J., Jones, D.P., 2000. Rat jejunum controls luminal thiol–disulﬁde redox. J. Nutr.
130, 2739–2745.
Dayan, A.D., Paine, A.J., 2001. Mechanisms of chromium toxicity, carcinogenicity and al-
lergenicity: review of the literature from 1985 to 2000. Hum. Exp. Toxicol. 20,
439–451.
De Flora, S., D'Agostini, F., Balansky, R., Micale, R., Baluce, B., Izzotti, A., 2008. Lack of
genotoxic effects in hematopoietic and gastrointestinal cells of mice receiving
chromium(VI) with the drinking water. Mutat. Res. 659, 60–67.
Dennis Jr., G., Sherman, B.T., Hosack, D.A., Yang, J., Gao, W., Lane, H.C., Lempicki, R.A.,
2003. DAVID: Database for Annotation, Visualization, and Integrated Discovery.
Genome Biol. 4, P3.
Di Bona, K.R., Love, S., Rhodes, N.R., McAdory, D., Sinha, S.H., Kern, N., Kent, J., Strickland, J.,
Wilson, A., Beaird, J., Ramage, J., Rasco, J.F., Vincent, J.B., 2011. Chromium is not an es-
sential trace element for mammals: effects of a “low-chromium” diet. J. Biol. Inorg.
Chem. 16, 381–390.
Dickinson, D.A., Forman, H.J., 2002. Glutathione in defense and signaling: lessons from
a small thiol. Ann. N. Y. Acad. Sci. 973, 488–504.
Dos Santos Ferreira, V., Rocchetta, I., Conforti, V., Bench, S., Feldman, R., Levin, M.J.,
2007. Gene expression patterns in Euglena gracilis: insights into the cellular re-
sponse to environmental stress. Gene 389, 136–145.
Ebert, B., Kisiela, M., Malatkova, P., El-Hawari, Y., Maser, E., 2010. Regulation of human
carbonyl reductase 3 (CBR3; SDR21C2) expression by Nrf2 in cultured cancer cells.
Biochemistry 49, 8499–8511.
Eckel, J.E., Gennings, C., Chinchilli, V.M., Burgoon, L.D., Zacharewski, T.R., 2004. Empir-
ical Bayes gene screening tool for time-course or dose–response microarray data. J.
Biopharm. Stat. 14, 647–670.
Eckel, J.E., Gennings, C., Therneau, T.M., Burgoon, L.D., Boverhof, D.R., Zacharewski, T.R.,
2005. Normalization of two-channel microarray experiments: a semiparametric
approach. Bioinformatics 21, 1078–1083.
Elliott, P.J., Zollner, T.M., Boehncke, W.H., 2003. Proteasome inhibition: a new anti-
inﬂammatory strategy. J. Mol. Med. 81, 235–245.
Franco, R., Cidlowski, J.A., 2009. Apoptosis and glutathione: beyond an antioxidant. Cell
Death Differ. 16, 1303–1314.
Gavin, I.M., Gillis, B., Arbieva, Z., Prabhakar, B.S., 2007. Identiﬁcation of human cell re-
sponses to hexavalent chromium. Environ. Mol. Mutagen. 48, 650–657.
Gelin, A., Redrejo-Rodriguez, M., Laval, J., Fedorova, O.S., Saparbaev, M., Ishchenko, A.A.,
2010. Genetic and biochemical characterization of human AP endonuclease 1 mu-
tants deﬁcient in nucleotide incision repair activity. PLoS One 5, e12241.
26 A.K. Kopec et al. / Toxicology and Applied Pharmacology 259 (2012) 13–26Go, Y.M., Craige, S.E., Orr, M., Gernert, K.M., Jones, D.P., 2009. Gene and protein re-
sponses of human monocytes to extracellular cysteine redox potential. Toxicol.
Sci. 112, 354–362.
Han, D., Hanawa, N., Saberi, B., Kaplowitz, N., 2006. Mechanisms of liver injury. III. Role
of glutathione redox status in liver injury. Am. J. Physiol. Gastrointest. Liver Physiol.
291, G1–G7.
Henics, T., Wheatley, D.N., 1999. Cytoplasmic vacuolation, adaptation and cell death: a
view on new perspectives and features. Biology of the cell/under the auspices of
the European Cell Biology Organization, 91, pp. 485–498.
Hook, S.E., Skillman, A.D., Gopalan, B., Small, J.A., Schultz, I.R., 2008. Gene expression
proﬁles in rainbow trout, Onchorynchus mykiss, exposed to a simple chemical mix-
ture. Toxicol. Sci. 102, 42–60.
IARC, 1990. Chromium, nickel and welding. IARC Monogr Eval Carcinog Risks Hum. ,
pp. 49–256. Lyon.
Izzotti, A., Cartiglia, C., Balansky, R., D'Agostini, F., Longobardi, M., De Flora, S., 2002. Se-
lective induction of gene expression in rat lung by hexavalent chromium. Mol. Car-
cinog. 35, 75–84.
Joseph, P., He, Q., Umbright, C., 2008. Heme-oxygenase 1 gene expression is a marker
for hexavalent chromium-induced stress and toxicity in human dermal ﬁbroblasts.
Toxicol. Sci. 103, 325–334.
Kass, E.M., Jasin, M., 2010. Collaboration and competition between DNA double-strand
break repair pathways. FEBS Lett. 584, 3703–3708.
Katz, S.A., Salem, H., 1993. The toxicology of chromium with respect to its chemical
speciation: a review. J. Appl. Toxicol. 13, 217–224.
Mannery, Y.O., Ziegler, T.R., Hao, L., Shyntum, Y., Jones, D.P., 2010. Characterization of
apical and basal thiol–disulﬁde redox regulation in human colonic epithelial
cells. Am. J. Physiol. Gastrointest. Liver Physiol. 299, G523–G530.
Mayrhofer, G., 1995. Absorption and presentation of antigens by epithelial cells of the
small intestine: hypotheses and predictions relating to the pathogenesis of coeliac
disease. Immunol. Cell Biol. 73, 433–439.
McCarroll, N., Keshava, N., Chen, J., Akerman, G., Kligerman, A., Rinde, E., 2010. An evaluation
of the mode of action framework for mutagenic carcinogens case study II: chromium
(VI). Environ. Mol. Mutagen. 51, 89–111.
Mimnaugh, E.G., Xu, W., Vos, M., Yuan, X., Neckers, L., 2006. Endoplasmic reticulum
vacuolization and valosin-containing protein relocalization result from simulta-
neous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade.
Mol. Cancer Res. 4, 667–681.
Moriarty-Craige, S.E., Jones, D.P., 2004. Extracellular thiols and thiol/disulﬁde redox in
metabolism. Annu. Rev. Nutr. 24, 481–509.
Myers, J.M., Antholine, W.E., Myers, C.R., 2011. The intracellular redox stress caused by
hexavalent chromium is selective for proteins that have key roles in cell survival
and thiol redox control. Toxicology 281, 37–47.
Nemec, A.A., Zubritsky, L.M., Barchowsky, A., 2010. Chromium(VI) stimulates Fyn to
initiate innate immune gene induction in human airway epithelial cells. Chem.
Res. Toxicol. 23, 396–404.
Neurath, M.F., Becker, C., Barbulescu, K., 1998. Role of NF-kappaB in immune and in-
ﬂammatory responses in the gut. Gut 43, 856–860.
NTP, 2007. NTP technical report on the toxicity studies of sodium dichromate dihydrate
(CAS no. 7789-12-0) administered in drinking water to male and female F344/N
rats and B6C3F1 mice and male BALB/c and am3-C57BL/6 mice. Natl Toxicol Program
Tech Rep Ser, pp. 1–144.
NTP, 2008. NTP technical report on the toxicology and carcinogenesis studies of sodium
dichromate dihydrate (CAS No. 7789-12-0) in F344/N rats and B6C3F1 mice
(drinking water studies). Natl Toxicol Program Tech Rep Ser, pp. 1–192.
O'Brien, T.J., Ceryak, S., Patierno, S.R., 2003. Complexities of chromium carcinogenesis:
role of cellular response, repair and recovery mechanisms. Mutat. Res. 533, 3–36.
Oze, C., Bird, D.K., Fendorf, S., 2007. Genesis of hexavalent chromium from natural
sources in soil and groundwater. Proc. Natl. Acad. Sci. U. S. A. 104, 6544–6549.
Powell, C.L., Kosyk, O., Ross, P.K., Schoonhoven, R., Boysen, G., Swenberg, J.A., Heinloth,
A.N., Boorman, G.A., Cunningham, M.L., Paules, R.S., Rusyn, I., 2006. Phenotypic an-
choring of acetaminophen-induced oxidative stress with gene expression proﬁles
in rat liver. Toxicol. Sci. 93, 213–222.Pritchard, D.E., Ceryak, S., Ramsey, K.E., O'Brien, T.J., Ha, L., Fornsaglio, J.L., Stephan, D.A.,
Patierno, S.R., 2005. Resistance to apoptosis, increased growth potential, and altered
gene expression in cells that survived genotoxic hexavalent chromium [Cr(VI)] expo-
sure. Mol. Cell. Biochem. 279, 169–181.
Proctor, D.M., Otani, J.M., Finley, B.L., Paustenbach, D.J., Bland, J.A., Speizer, N., Sargent, E.V.,
2002. Is hexavalent chromium carcinogenic via ingestion? Aweight-of-evidence review.
J. Toxicol. Environ. Health A 65, 701–746.
Reinstein, E., 2004. Immunologic aspects of protein degradation by the ubiquitin–proteasome
system. Isr. Med. Assoc. J. 6, 420–424.
Rusyn, I., Asakura, S., Pachkowski, B., Bradford, B.U., Denissenko, M.F., Peters, J.M.,
Holland, S.M., Reddy, J.K., Cunningham, M.L., Swenberg, J.A., 2004. Expression of
base excision DNA repair genes is a sensitive biomarker for in vivo detection of
chemical-induced chronic oxidative stress: identiﬁcation of the molecular source
of radicals responsible for DNA damage by peroxisome proliferators. Cancer Res.
64, 1050–1057.
Saeed, A.I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., Braisted, J., Klapa, M.,
Currier, T., Thiagarajan, M., Sturn, A., Snufﬁn, M., Rezantsev, A., Popov, D., Ryltsov,
A., Kostukovich, E., Borisovsky, I., Liu, Z., Vinsavich, A., Trush, V., Quackenbush, J.,
2003. TM4: a free, open-source system for microarray data management and anal-
ysis. Biotechniques 34, 374–378.
Shi, X., Chiu, A., Chen, C.T., Halliwell, B., Castranova, V., Vallyathan, V., 1999. Reduction
of chromium(VI) and its relationship to carcinogenesis. J. Toxicol. Environ. Health
B Crit. Rev. 2, 87–104.
Shrivastava, R., Kannan, A., Upreti, R.K., Chaturvedi, U.C., 2005. Effects of chromium on
the resident gut bacteria of rat. Toxicol. Mech. Methods 15, 211–218.
Sun, H., Clancy, H.A., Kluz, T., Zavadil, J., Costa, M., 2011. Comparison of gene expression
proﬁles in chromate transformed BEAS-2B cells. PLoS One 6, e17982.
Thomas, R.S., Allen, B.C., Nong, A., Yang, L., Bermudez, E., Clewell III, H.J., Andersen, M.E.,
2007. A method to integrate benchmark dose estimates with genomic data to as-
sess the functional effects of chemical exposure. Toxicol. Sci. 98, 240–248.
Thompson, C.M., Haws, L.C., Harris, M.A., Gatto, N.M., Proctor, D.M., 2011a. Application of the
U.S. EPAmodeof action. Framework for purposes of guiding future research: a case study
involving the oral carcinogenicity of hexavalent chromium. Toxicol. Sci. 119, 20–40.
Thompson, C.M., Proctor, D.M., Haws, L.C., Hébert, C.D., Grimer, S.D., Shertzer, H.G.,
Kopec, A.K., Hixon, G., Zacharewski, T.R., Harris, M.A., 2011b. Investigation of the
mode of action underlying the tumorigenic response induced in B6C3F1 mice ex-
posed orally to hexavalent chromium. Toxicol. Sci. 123, 58–70.
Townsend, D.M., 2007. S-glutathionylation: indicator of cell stress and regulator of the
unfolded protein response. Mol. Interv. 7, 313–324.
Upreti, R.K., Shrivastava, R., Kannan, A., Chaturvedi, U.C., 2005. A comparative study on
rat intestinal epithelial cells and resident gut bacteria: (I) effect of hexavalent
chromium. Toxicol. Mech. Methods 15, 331–338.
U.S. EPA, 2010. IRIS Toxicological Review of Hexavalent Chromium (External Review
Draft), EPA/635/R-10/004A. U.S. Environmental Protection Agency, Washinton, D.C.
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., Speleman, F.,
2002. Accurate normalization of real-time quantitative RT-PCRdata by geometric aver-
aging of multiple internal control genes. Genome Biol. 3 RESEARCH0034.
Vincent, J.B., 2004. Recent advances in the nutritional biochemistry of trivalent chromi-
um. Proc. Nutr. Soc. 63, 41–47.
Watson, J.D., Oster, S.K., Shago, M., Khosravi, F., Penn, L.Z., 2002. Identifying genes reg-
ulated in a Myc-dependent manner. J. Biol. Chem. 277, 36921–36930.
Yamada, K., Sato, K., Morishita, S., Kaminogawa, S., Totsuka, M., 2009. Establishment of
a primary culture method for mouse intestinal epithelial cells by organ culture of
fetal small intestine. Biosci. Biotechnol. Biochem. 73, 1849–1855.
Yang, L., Allen, B.C., Thomas, R.S., 2007. BMDExpress: a software tool for the benchmark
dose analyses of genomic data. BMC Genomics 8, 387.
Ye, J., Shi, X., 2001. Gene expression proﬁle in response to chromium-induced cell
stress in A549 cells. Mol. Cell. Biochem. 222, 189–197.
Yusof, A.M., Malek, N.A., 2009. Removal of Cr(VI) and As(V) from aqueous solutions by
HDTMA-modiﬁed zeolite Y. J. Hazard. Mater. 162, 1019–1024.
Zhitkovich, A., 2011. Chromium in drinking water: sources, metabolism and cancer
risks. Chem. Res. Toxicol. 24, 1617–1629.
